LIVE FROM INTERPHEX

Tech and Regulatory Issues? Biotech/Manufacturing Firms Discuss

Loading the player...

Purification bottlenecks, integrating single-use technologies and low cost companies are just some of the issues affecting the biotech industry today, according to experts at this year’s Interphex.

In-Pharmatechnologist.com spoke to several companies at this year’s show in New York in order to assess the situation in the biotech industry at present. Companies including Pall Corporation, Baxter and Sartorius all gave their opinion on what the biggest technical problem was facing their industry today and whether any specific regulations were needed to address this.

There was some common ground amongst the companies, especially with regards to single-use technology. Vicas Gupta, from GE Healthcare told us that customers are looking “for complete single-use offerings from start to finish and most of the competitors in this space are striving to offer that complete portfolio.”

This was backed by Helene Pora – VP of Single-Use Systems at Pall – who also described the issues of incorporating new single-use technologies when clients are looking at multiple products.

As for regulations, biomanufacturer Baxter spoke of its concerns that there were actually too many at present. Mico Holguin said:

“If anything we’re trying to find a way to work with the appropriate agencies to minimize the amount of regulations, especially the documentation required and the oversight.”

ASI Life Science, however, was concerned that regulations did not currently cover standardisation in testing, whilst Sartorius focused on the present economic situation which had invited a number of smaller companies into the market, and thus regulatory bodies needed to check their materials, processes and documentation and “not look so much at the dollar sign.”

Related News

ASI and Chromatan talk Single-use at NY Interphex

Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal

Sartorius unveils new microbial gas sensor

Sartorius and BlueSens Partner on Microbial Gas Sensor Tech

Sartorius: Demand in Europe and Asia Offsets Decline North America

Sartorius: Single-Use Demand in Europe and Asia Offsets Rev Decline North America

Baxter Bolsters German Bio-Plant with New Packaging Line

Baxter Bolsters German Bio-Plant with New Packaging Line

Single-Use Growth Offsets Pall's Muted Results

Single-Use Growth Offsets Pall's Muted Results

New culture dish tech can cut plant QC sample contamination says SSB

New culture dish tech can cut plant QC sample contamination says SSB

New Pall single-use TFF tech attracts attention

New Pall single-use TFF tech attracts attention

Sartorius tries to TAP into demand for small-scale single-use tech

Pall opens CofE in Shanghai, China

Pall opens Centre of Excellence in Shanghai

TAP approves Sartorius $45m takeover bid

TAP approves Sartorius $45m takeover bid

ATMI's bioreactors will fill gaps in Pall's end-to-end solutions

Pall CEO: ATMI deal doesn't rule out other acquisitions

Baxter is spinning off its biopharma operations

Baxter spin-off to focus on biosimilars and haematology growth

Integrating single-use into existing facilities still a challenge, says ASI

Integrity test helps assure no flaws in single-use systems, says ASI

Integrity test helps assure no flaws in single-use systems, says ASI

Catalent to replace steel bioreactors with single use

Catalent plans single use overhaul of bioreactors

Single-use drug production tech: ATMI

ATMI gears up for single-use "boom" for biotech industry

ATMI single-use bioprocessing system

ATMI: Single Use Bioreactors on the Up, but US Tails Europe

The single-use age has dawned, says ThermoFisher

The single-use age has dawned, says ThermoFisher

Single use tech for biopharma: Pall and Thermo Fisher

The quest for more understanding is behind the single use boom: Pall and Thermo Fisher

GE pockets single-use biotech firm

The demand for HP production is growing, and Alkermes says contract manufacturers will swipe a big portion of the market

Single-use lets some Pharmas make own potent drugs but outsourcing demand still strong: Alkermes

Related Products

See more related products